Recent Updates
Recently added Catalysts

ACTOS

Phase 1

Multiple Sclerosis, Relapsing-Remitting | Small molecule | Neurology |Takeda Pharmaceutical Company Limited|Last Updated: Jul 22, 2019

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment30

FDA Designations

No designations recorded

Clinical trial landscape

ACTOS · 1 trial · 1 indication

Phase 1 1
NCT00242177Pilot Test of ACTOS in Multiple Sclerosis: Safety and TolerabilityMultiple Sclerosis, Relapsing-Remitting
COMPLETED30 Analytics
PHASE1COMPLETED
Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability
Multiple Sclerosis, Relapsing-Remitting
NCT0024217730
Unlock trial analytics

Study Endpoints

Primary Endpoints

MRI with GD enhancement at visit 2, 5, 8
Blood test (CBC, Liver enzymes)at each visit
EDSS at each visit
MSFC at each visit
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Interventions

NameTypeDescription
ACTOS (Pioglitazone)DRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: Informed consent must be signed and dated Clinically or laboratory definite RR MS Mild symptoms, with current EDSS between 1 and 6.5, and ambulatory Currently taking, and history (\>= 1 year) of taking Avonex or Rebif No relapses in past 3 months Historical annual relapse rate o...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about ACTOS

What is ACTOS used for in Multiple Sclerosis?

ACTOS is being studied for use in relapsing-remitting multiple sclerosis. It is an investigational small molecule in Phase 1 clinical development for this neurological condition. The drug is being evaluated for safety and tolerability in patients with this form of multiple sclerosis.

What does ACTOS target?

ACTOS is a small molecule therapeutic being developed for relapsing-remitting multiple sclerosis. The specific molecular target of ACTOS has not been disclosed in the available clinical trial information. The drug is currently in Phase 1 clinical development for this neurological indication.

Who makes ACTOS?

ACTOS is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker symbol TAK. The company is conducting clinical research on this small molecule for the treatment of relapsing-remitting multiple sclerosis.

What phase is ACTOS in?

ACTOS is in Phase 1 clinical development for relapsing-remitting multiple sclerosis. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed, with no active trials currently ongoing.

What clinical trials is ACTOS in?

ACTOS has one completed clinical trial, NCT00242177, titled 'Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability.' This Phase 1 study enrolled 30 participants with relapsing-remitting multiple sclerosis in the United States. The trial was randomized, double-blind, and uncontrolled.

Is ACTOS the same as pioglitazone?

ACTOS is the brand name for pioglitazone, a drug that is being investigated for relapsing-remitting multiple sclerosis. In the clinical trial NCT00242177, ACTOS is being tested as a small molecule therapeutic for this neurological condition.